Heparanase-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Heparanase-2 (HPSE2; UniProt Q8WWQ2), expressed in HEK293. A catalytically inactive heparan sulfate-binding protein used to study HPSE inhibition, ECM biology, and urofacial syndrome genetics.
Expression system
HEK293
Cat. #
REC-Heparanase2

In stock

SKU
REC-Heparanase2
$498.00

Target Overview

Heparanase-2 (HPSE2; UniProt Q8WWQ2) is a 592-amino-acid secreted glycoprotein that belongs to the same family as the endo-β-glucuronidase heparanase (HPSE1) but is enzymatically inactive. Despite sharing structural homology with HPSE1, HPSE2 lacks the catalytic residues required for heparan sulfate chain cleavage. Instead, it binds heparin and heparan sulfate proteoglycans with high affinity and inhibits HPSE1 activity in vitro, most likely through substrate competition. HPSE2 is secreted and associates with the extracellular matrix, placing it at the interface of heparan sulfate remodelling and extracellular signalling. This recombinant is produced in HEK293 mammalian cells, which supports the post-translational processing — glycosylation in particular — appropriate for a secreted extracellular protein. Mammalian expression is especially relevant for researchers studying HPSE2's interaction with heparan sulfate proteoglycans or its inhibitory relationship with HPSE1, where native-like folding and glycan context may influence binding affinity and specificity. Researchers use this recombinant in several experimental contexts: competitive binding assays examining HPSE2's displacement of HPSE1 from heparan sulfate substrates; surface plasmon resonance or biolayer interferometry studies measuring heparin-binding kinetics; and cell-based assays investigating HPSE2's effect on extracellular matrix composition. The recombinant also serves as a well-characterised positive control antigen for Western blot and immunohistochemistry validation. Researchers selecting this reagent for antibody validation can pair it directly with the matched Triple Point Biologics anti-Heparanase-2 antibody (SKU: RP-Heparanase2), which is cross-referenced on the product page.

Background

Heparanase-2 (HPSE2) was identified on the basis of sequence homology to the enzymatically active heparanase HPSE1, but subsequent biochemical characterisation established that HPSE2 is catalytically inert with respect to heparan sulfate cleavage. Its biological role appears to be modulatory: by binding heparan sulfate and heparin with high affinity, HPSE2 can effectively limit HPSE1 access to substrate, dampening the heparan sulfate remodelling activity that HPSE1 drives in tumour invasion, angiogenesis, and inflammatory signalling contexts. This functional antagonism has made HPSE2 a subject of interest wherever HPSE1 biology is studied. The clearest disease link for HPSE2 comes from loss-of-function genetics. Biallelic pathogenic variants in HPSE2 cause urofacial syndrome (UFS, also called Ochoa syndrome), a rare autosomal recessive disorder characterised by dysfunctional voiding and an inverted facial expression during smiling. A 2025 case report by Del Valle-Pérez et al. (PMID 39150614) describes a founder pathogenic variant in HPSE2 segregating with UFS in an isolated pedigree, reinforcing HPSE2 as the canonical UFS locus and providing a clinical reference point for researchers modelling the syndrome in vitro or in animal systems. Beyond UFS, HPSE2 expression has been identified in transcriptomic and network analyses of complex diseases. A 2025 machine-learning study by Nojima (PMID 40580591) examining molecular network differences between idiopathic pulmonary fibrosis and lung squamous cell carcinoma flagged HPSE2 among genes with differential network connectivity, consistent with a broader role for heparan sulfate remodelling pathways in fibrotic and neoplastic lung biology. The broader heparanase family has been reviewed comprehensively by Vahdatahar et al. (PMID 40899692, FASEB J 2025), which frames HPSE2's evolutionary and structural context relative to active heparanases across tissues. For researchers characterising the HPSE1/HPSE2 axis, this recombinant provides a defined, mammalian-expressed source of HPSE2 suitable for binding studies, inhibition assays, and as an immunoreactive standard. Expression in HEK293 cells preserves glycosylation patterns relevant to extracellular matrix interactions, distinguishing it from bacterially derived material. Validated human species reactivity is confirmed; reactivity with other species is predicted based on sequence conservation and should be experimentally confirmed by the investigator.

Applications

  • Competitive heparan sulfate binding assay to characterise HPSE2-mediated inhibition of HPSE1 substrate access
  • Surface plasmon resonance or biolayer interferometry to measure heparin-binding kinetics (kon, koff, KD) of recombinant HPSE2
  • Western blot positive control antigen for anti-HPSE2 antibody validation (pair with TPB SKU RP-Heparanase2)
  • Immunohistochemistry antigen standard for titration and specificity confirmation of anti-HPSE2 antibodies
  • ELISA capture or detection standard for quantification of HPSE2 in conditioned medium or tissue lysates
  • Cell-based extracellular matrix remodelling assay: exogenous addition to measure effect on HPSE1-driven heparan sulfate shedding
  • Pull-down or co-immunoprecipitation assay to identify HPSE2 protein-protein interaction partners in ECM fractions

References

  1. Vahdatahar E et al. The Pathophysiological Functions of Heparanases: From Evolution, Structural and Tissue-Specific Perspectives. FASEB J. 2025. doi:10.1096/fj.202501859R (PMID 40899692)
  2. Nojima Y. Identification of the differences in molecular networks between idiopathic pulmonary fibrosis and lung squamous cell carcinoma using machine learning. Comput Biol Chem. 2025. doi:10.1016/j.compbiolchem.2025.108560 (PMID 40580591)
  3. Del Valle-Pérez M et al. Urofacial (Ochoa) syndrome with a founder pathogenic variant in the HPSE2 gene: a case report and mutation origin. J Appl Genet. 2025. doi:10.1007/s13353-024-00896-7 (PMID 39150614)
  4. Kim JP et al. Whole-genome sequencing analyses suggest novel genetic factors associated with Alzheimer's disease and a cumulative effects model for risk liability. Nat Commun. 2025. doi:10.1038/s41467-025-59949-y (PMID 40419521)
  5. Petersen LM et al. A Systematic, Evidence-Based Workflow for Classifying KMT2A Fusions in Acute Myeloid Leukemia. J Mol Diagn. 2025. doi:10.1016/j.jmoldx.2025.06.007 (PMID 40706988)

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight should I expect for recombinant Heparanase-2 on SDS-PAGE or Western blot?

The HPSE2 polypeptide backbone is 592 amino acids, giving a calculated MW of approximately 65 kDa. However, HPSE2 is a secreted glycoprotein produced here in HEK293 cells, so native-like N-glycosylation pushes the apparent MW on SDS-PAGE to roughly 72–80 kDa under denaturing, reducing conditions. Run alongside a broad-range ladder and expect a diffuse or slightly smeared band — characteristic of glycoproteins. If you see a sharper band near 65 kDa, partial deglycosylation during sample prep is the likely cause. PNGase F treatment will collapse the band to ~65 kDa as a useful control.

Does recombinant HPSE2 have heparanase enzymatic activity or is it catalytically inactive?

HPSE2 is catalytically inactive. Unlike HPSE1, it lacks the two glutamate residues (E225 and E343 in HPSE1) that constitute the endo-β-glucuronidase active site. This recombinant will not cleave heparan sulfate chains. Its documented biological function is inhibitory: HPSE2 binds heparin and heparan sulfate proteoglycans with high affinity and competes with HPSE1 for substrate access, suppressing HPSE1-mediated HS degradation. If you are designing an HPSE1 inhibition assay, HPSE2 serves as the inhibitory protein, not the enzyme. Use active recombinant HPSE1 as the enzymatic component.

How do I set up an HPSE1 inhibition assay using recombinant Heparanase-2?

Use a fluorometric heparan sulfate degradation assay with HPSE1 as the enzyme and BODIPY- or FITC-labeled heparan sulfate as substrate. Pre-incubate recombinant HPSE2 with the HS substrate for 15–30 min at room temperature before adding HPSE1 to allow competitive binding. HPSE1 assay buffer (50 mM sodium acetate pH 5.0, 150 mM NaCl) is compatible with this recombinant. Titrate HPSE2 from 10 nM to 1 µM to establish the inhibitory curve. Published IC50 values for HPSE2 inhibition of HPSE1 fall in the 50–200 nM range depending on substrate concentration and assay format.

What buffer is recombinant Heparanase-2 supplied in and can I dilute it directly into my assay?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For HPSE1 inhibition assays run at pH 5.0 (sodium acetate buffer), dilute HPSE2 at least 1:5–1:10 into your assay buffer immediately before use so the Tris and glycerol contribution is negligible. Avoid repeated freeze-thaw; working aliquots can be held at 4°C for up to 48 hours. Add 0.1% BSA as a carrier if diluting below 10 nM to prevent adsorptive losses on tube surfaces. Do not sonicate or vortex — mix by gentle pipetting.

What starting concentration of recombinant Heparanase-2 is recommended for heparin binding or SPR binding experiments?

For surface plasmon resonance or biolayer interferometry with heparin-coated chips, start at 100–500 nM HPSE2 in running buffer (PBS or 50 mM HEPES pH 7.4, 150 mM NaCl, 0.05% Tween-20). KD values for HPSE2–heparin interactions reported in the literature are in the low nanomolar to sub-nanomolar range, so use a concentration series spanning 1–500 nM for full kinetic fitting. For pull-down or co-precipitation with heparan sulfate proteoglycans in cell lysates, 200–500 nM recombinant HPSE2 per reaction is a reasonable starting point. Confirm protein integrity by SDS-PAGE before each experiment.

Can I use recombinant Heparanase-2 as a positive control for Western blot with the matched anti-heparanase-2 antibody?

Yes — this is one of the primary intended uses. The matched rabbit polyclonal antibody (SKU: RP-Heparanase2; see /anti-heparanase-2-rabbit-polyclonal-antibody) was raised and validated in the same laboratory that produced this recombinant, so compatibility is confirmed rather than assumed. Load 20–50 ng of recombinant HPSE2 per lane on a 10% SDS-PAGE gel. Expect a band at ~72–80 kDa. This lane gives you a clean, reproducible reference band alongside your cell lysate or tissue samples, which is particularly useful when endogenous HPSE2 expression is low.

How much recombinant Heparanase-2 should I load for Western blot positive control and what antibody dilution should I use?

Load 20–50 ng of recombinant HPSE2 per lane. At 50 ng, the band at ~72–80 kDa is clearly detectable; dropping to 20 ng still gives a usable signal and keeps the positive control lane from overwhelming your chemiluminescent exposure. For the matched antibody RP-Heparanase2, a primary dilution of 1:500–1:2000 in 5% non-fat milk/TBST is a reasonable starting range — refer to the antibody datasheet for lot-specific recommendations. Use standard HRP-conjugated anti-rabbit secondary at 1:5000–1:10,000. Purity of this recombinant is >95% by SDS-PAGE, so no contaminating bands should confound interpretation.

What are the storage and shelf life conditions for recombinant Heparanase-2 and how do I handle aliquots?

Store at -20°C in single-use aliquots immediately upon receipt. Under these conditions, the protein is stable for at least 12 months. Once thawed, keep on ice and use within 24–48 hours; do not refreeze. Repeated freeze-thaw cycles cause aggregation and activity loss for most glycoproteins — HPSE2 is no exception. Aliquot size should match your typical experiment: for inhibition assays consuming 200–500 nM per well, a 10 µg aliquot covers multiple runs. Purity is >95% by SDS-PAGE and endotoxin is <0.1 EU/µg by LAL assay, so the preparation is suitable for cell-based experiments without additional endotoxin removal.

Validation imagery coming soon

Western blot validation figures for REC-Heparanase2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →